Figure 3.

Proliferative and suppressive capacity of CD4⁺CD25⁺ T cells isolated from peripheral blood in patients with chronic myeloid leukemia from three different tyrosine kinase inhibitor treatment groups at 3 and 6 months following treatment. ‘Resting’ is a negative control without CFSE. Treatment with (A) imatinib, (B) dasatinib and (C) nilotinib. (D) Proliferation of CD4⁺CD25- T cells decreased when incubated with CD4⁺CD25⁺ T cells. (E) imatinib (F) dasatinib and (G) nilotinib. CD4⁺CD25- T cells and CD4⁺CD25⁺ T cells were co-cultured either alone or at a 1:1 ratio. CD, cluster of differentiation; CFSE, carboxyfluorescein diacetate succinimidyl ester. *P<0.05, **P<0.01 and ***P<0.0001.